Director, Global Medical Immunology & Cardiovascular, Portfolio Strategy & Business Development at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Deep scientific expertise in Immunology and/or Cardiovascular therapeutic areas
Strong strategic acumen and seasoned leadership experience
Ability to influence and collaborate across global and local teams
Experience in portfolio strategy, business development, and medical affairs

Responsibilities

Lead high-impact strategic initiatives in partnership with Global Medical ICV Portfolio Strategy & Business Development Leads
Translate strategy into actionable projects to drive successful delivery of project objectives
Provide strategic oversight for portfolio alignment across medical and commercial functions, including governance of MSAs, CDAs, and external advisory engagements
Synthesize insights from clinical research, epidemiology, patient journey mapping, and competitive intelligence to inform portfolio decisions
Direct business development assessments and market research activities, ensuring alignment with Commercial, Clinical Development, and CV Discovery
Oversee execution of global medical planning for early assets, ensuring strategic impact and readiness for development milestones
Provide strategic guidance for medical advisory boards to optimize early development assets for unmet medical needs
Partner with Commercial and R&D teams to embed medical insights into development and commercialization strategies
Facilitate cross-functional collaboration to ensure seamless integration of medical strategy into broader enterprise goals
Strategically manage budgets in alignment with departmental objectives, identifying strategic activities based on business priorities, and ensuring optimal resource allocation, flexibility, and prioritization of projects
Support governance frameworks such as ICN APOC and contribute to strategic trade-off discussions and pipeline optimization
Champion initiatives that elevate talent, foster cross-pollination, and support career development within the ICV medical structure

Skills

Portfolio Strategy

Business Development

Immunology

Cardiovascular

Medical Affairs

Strategic Planning

Cross-functional Alignment

Scientific Expertise

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free